

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

DePuy Orthopaedics, Incorporated Correne Ramy Regulatory Affairs Associate 700 Orthopaedic Drive Warsaw, Indiana 46582 September 25, 2015

Re: K150862

Trade/Device Name: DePuy Actis DuoFix Hip Prosthesis

Regulation Number: 21 CFR 888.3353

Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or

nonporous uncemented prosthesis

Regulatory Class: Class II

Product Code: MEH, LPH, KWL, KWY

Dated: September 2, 2015 Received: September 4, 2015

Dear Ms. Ramy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

| 510 (k) | K150862 Number (if known): | | | | |
|--------------------|--|--|--|--|--|
| Device | Name: DePuy Actis DuoFix Hip Prosthesis | | | | |
| Indicat | ions for Use: | | | | |
| Total conditi | hip replacement or hip arthroplasty is indicated in the following ons: | | | | |
| | A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia. | | | | |
| | Avascular necrosis of the femoral head. | | | | |
| | . Acute traumatic fracture of the femoral head or neck. | | | | |
| ; | Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemi-arthroplasty, surface replacement arthroplasty, or total hip replacement. | | | | |
| | Certain cases of ankylosis. | | | | |
| Partial conditi | hip replacement or hip hemi-arthroplasty is indicated in the following | | | | |
| | Acute fracture of the femoral head or neck that cannot be appropriately | | | | |
| | reduced and treated with internal fixation. | | | | |
| | Fracture dislocation of the hip that cannot be appropriately reduced and | | | | |
| | treated with internal fixation. | | | | |
| | Avascular necrosis of the femoral head. | | | | |
| | Non-union of femoral neck fractures.Certain high subcapital and femoral neck fractures in the elderly. | | | | |
| 6. | | | | | |
| 7. | Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemi-arthroplasty. | | | | |
| The Ac | tis DuoFix Hip Prosthesis is indicated for cementless use only. | | | | |
| _ | | | | | |
| | scription Use X Over-The-Counter Use AND/OR Over-The-Counter Use | | | | |
| (Pa | rt 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) | | | | |
| (F | Please do not write below this line. Continue on another page if needed.) | | | | |

510 (k) Summary

(As required by 21 CFR 807.92 and 21 CFR 807.93)

| Submitter Information | Submitter Information | | | | | | |
|--------------------------------------|--|--|--|--|--|--|--|
| Name | DePuy Orthopaedics | | | | | | |
| Address | 700 Orthopedic Drive | | | | | | |
| | Warsaw, IN 46582 | | | | | | |
| Phone number | 574-371-4981 | | | | | | |
| Fax number | 574- 371-4987 | | | | | | |
| Establishment Registration Number | 1818910 | | | | | | |
| Name of contact person | Correne Ramy | | | | | | |
| Date prepared | March 31, 2015 | | | | | | |
| Name of device | | | | | | | |
| Trade or proprietary name | DePuy Actis DuoFix Hip Prosthesis | | | | | | |
| Common or usual name | Uncemented Hip Prosthesis | | | | | | |
| Classification name | Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis | | | | | | |
| | Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis | | | | | | |
| | Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis | | | | | | |
| | Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis | | | | | | |
| Class | П | | | | | | |
| Classification panel | 87 Orthopedics | | | | | | |
| Regulation | 21 CFR 888.3358, 888.3353, 888.3360, 888.3390 | | | | | | |
| Product Code(s) | LPH, MEH, KWL, KWY | | | | | | |
| Legally marketed device(s) to which | DePuy Summit DuoFix Hip Prosthesis (K011489, cleared July 31, 2001) | | | | | | |
| equivalence is claimed | DePuy Corail AMT Hip Prosthesis (K123991, cleared September 16, 2013) | | | | | | |
| Reason for 510(k) submission | New hip prosthesis | | | | | | |
| Device description | The DePuy Actis DuoFix prostheses are manufactured from forged titanium alloy (Ti-6Al-4V) and have a sintered commercially pure titanium bead porous coating (Porocoat®) and thin layer of plasma-sprayed hydroxyapatite (HA) coating. | | | | | | |

| | The stem consists of a wide range of stem neck designs and sizes allowing an accurate anatomical match for each patient. The stems are compatible with both unipolar and bipolar heads intended for hemi-arthroplasty and with modular metal and ceramic femoral heads intended for total hip arthroplasty. | | |
|----------------------------|--|--|--|
| Intended use of the device | Total inpartitioplasty and norm-inpartitioplasty | | |
| Indications for use | Total hip replacement or hip arthroplasty is indicated in the following conditions: 1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia. 2. Avascular necrosis of the femoral head. 3. Acute traumatic fracture of the femoral head or neck. 4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement. 5. Certain cases of ankylosis. Partial hip replacement or hip hemi-arthroplasty is indicated in the following conditions: 1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation. 2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation. 3. Avascular necrosis of the femoral head. 4. Non-union of femoral neck fractures. 5. Certain high subcapital and femoral neck fractures in the elderly. 6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement. 7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemi-arthroplasty. The Actis DuoFix Hip Prosthesis is indicated for cementless use only. | | |

SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO

| THE PREDICATE DEVICE THE DEVICE COMPARED TO | | | | | | |
|--|---|--|---|--|--|--|
| Characteristics | Subject Device: DePuy Actis DuoFix Hip Prosthesis | Predicate Device: DePuy Summit DuoFix Hip Prosthesis (K011489) | Predicate Device: DePuy Corail AMT Hip Prosthesis (K123991) | | | |
| Intended Use | Total Hip Arthroplasty, Hemi-Hip Arthroplasty | Total Hip Arthroplasty, | Total Hip Arthroplasty Hemi-Hip Arthroplasty | | | |
| Material | Ti-6AL-4V with Porocoat and plasma sprayed HA coating | Ti-6AL-4V with Porocoat and plasma sprayed HA coating | Ti-6AL-4V with plasma sprayed HA coating | | | |
| Fixation | Uncemented | Uncemented | Uncemented | | | |
| | | | | | | |
| Stem Size | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 | 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20 | | | |
| Neck Offset | Standard, High | Standard, High | Standard, High | | | |
| Collar | Collared | Collarless | Collared, Collarless | | | |
| | | | | | | |
| Sterile Method | Gamma | Same | Same | | | |
| Packaging | Double PETG blister with Tyvek peel lid | Same | Same | | | |
| Shelf Life | 10 years | Same | Same | | | |
| PERFORMANCE DATA | | | | | | |

SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE

Distal fatigue, neck fatigue, range of motion, biocompatibility

SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION

No clinical tests were conducted to demonstrate substantial equivalence.

CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA

The subject DePuy Actis DuoFix hip stems are substantially equivalent to the predicates Summit DuoFix and DePuy Corail AMT hip prostheses.